SCHEMBL7417025

SCHEMBL7417025

CC(C)[C@@H](C=O)N(C)C(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.49
CTSB P07858 5/20 0.47
ALDH1A1 P00352 4/20 0.46
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
CCR6 P51684 1/20 0.42
PAX8 Q06710 1/20 0.42
CTSL P07711 3/20 0.42
CTSS P25774 3/20 0.42
CTSK P43235 3/20 0.42
HCAR2 Q8TDS4 1/20 0.42
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29789557 1.00 ABCB1 (0.49) ABCB1CTSBALDH1A1MAPTHPGD
SCHEMBL14966424 0.88 ABCB1 (0.49) ABCB1CTSBALDH1A1MAPTHPGD
SCHEMBL14962690 0.88 ABCB1 (0.49) ABCB1CTSBALDH1A1MAPTHPGD
SCHEMBL25100408 0.86 ABCB1 (0.39) ABCB1CTSBALDH1A1HPGDCTSL
SCHEMBL14304888 0.85 ABCB1 (0.51) ABCB1CTSBALDH1A1MAPTHPGD
SCHEMBL567436 0.85 ABCB1 (0.51) ABCB1CTSBALDH1A1MAPTHPGD
SCHEMBL25100442 0.82 ABCB1 (0.53) ABCB1CTSBALDH1A1MAPTHPGD
SCHEMBL8276259 0.82 ABCB1 (0.56) ABCB1CTSBALDH1A1MAPTHPGD
SCHEMBL6582855 0.81 CTSB (0.49) ABCB1CTSBALDH1A1MAPTHPGD
SCHEMBL13490098 0.81 ABCB1 (0.53) ABCB1CTSBALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11596693-B2 Antibody-drug conjugates and uses thereof MABPLEX INTERNATIONAL CO., LTD (CN) 2023-03-07 US disclosed
US-5733882-A Retroviral protease inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1998-03-31 US disclosed
EP-0602069-A4 RETROVIRAL PROTEASE INHIBITORS. SMITHKLINE BEECHAM CORP (US) 1995-05-03 EP disclosed
EP-0602069-A1 RETROVIRAL PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1994-06-22 EP disclosed
WO-1993002057-A1 RETROVIRAL PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1993-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11596693-B2 Antibody-drug conjugates and uses thereof DARS1, CD2, FCGR2A ABCB1 87/4885CTSB 3147/4885ALDH1A1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.